30 research outputs found

    Variants A189V and N680S of the human follicle-stimulating hormone (FSH) receptor : functional characterization and clinical involvement

    No full text
    La FSH est une hormone qui joue un rôle central dans la fonction de reproduction. De ce fait, elle est utilisée en assistance médicale à la procréation (AMP) afin de recruter un pool de follicules et de l’amener jusqu'à l'ovulation. La FSH agit sur un récepteur spécifique (RFSH) qui active des voies de signalisation par l'intermédiaire des protéines G et des β-arrestines. L'étude in vitro d’un mutant et de variants du RFSH décrits chez l’homme nous a permis de mettre en évidence différents mécanismes conduisant à des biais de signalisation de ce récepteur. Ces altérations génétiques, en modifiant l'équilibre qui existe entre les différentes voies de signalisation activées par le RFSH, conduisent à des manifestations cliniques. En parallèle, nous avons mené une étude clinique sur le polymorphisme N680S du RFSH, qui nous a permis de confirmer et de prolonger les résultats de la littérature tout en corrélant les résultats obtenus in vitro à la signalisation des récepteurs N680 et S680. L’ensemble de nos résultats ouvre des perspectives pour le développement de nouvelles stratégies en AMP.FSH is a hormone which is centrally involved in reproduction. For this reason, FSH is extensively used in in vitro fertilization (IVF) to recruit and lead a pool of follicle to ovulation. FSH acts on its cognate receptor (FSHR) which activates signaling pathways through the canonical G-protein pathways as well as through β-arrestin-dependent transduction mechanisms. In vitro studies of a mutant and of variants of the FSHR identified in patients allowed us to highlight different mechanisms leading to bias in the signaling pathways triggered by this receptor. These genetic alterations, by modifying the equilibrium that exists between the different signaling pathways activated by the FSHR, lead to clinical consequences. In parallel, we have carried out a clinical study centered on the N680S polymorphism of the FSHR. Our results confirm and extend previous studies from the literature while correlating the results we obtained in vitro with the functional consequences of the N680S polymorphism of the FSHR. Together, our results open new avenues for developing new strategies in IVF

    L' anémie chez le patient cancéreux adulte (de la physiopathologie au traitement)

    No full text
    POITIERS-BU MĂ©decine pharmacie (861942103) / SudocSudocFranceF

    Semi-quantitative measurement of specific proteins in human cumulus cells using reverse phase protein array

    No full text
    The ability to predict the developmental and implantation ability of embryos remains a major goal in human assisted-reproductive technology (ART) and most ART laboratories use morphological criteria to evaluate the oocyte competence despite the poor predictive value of this analysis. Transcriptomic and proteomic approaches on somatic cells surrounding the oocyte (granulosa cells, cumulus cells [CCs]) have been proposed for the identification of biomarkers of oocyte competence. We propose to use a Reverse Phase Protein Array (RPPA) approach to investigate new potential biomarkers of oocyte competence in human CCs at the protein level, an approach that is already used in cancer research to identify biomarkers in clinical diagnostics. Antibodies targeting proteins of interest were validated for their utilisation in RPPA by measuring siRNA-mediated knockdown efficiency in HEK293 cells in parallel with Western blotting (WB) and RPPA from the same lysates. The proteins of interests were measured by RPPA across 13 individual human CCs from four patients undergoing intracytoplasmic sperm injection procedure. The knockdown efficiency of VCL, RGS2 and SRC were measured in HEK293 cells by WB and by RPPA and were acceptable for VCL and SRC proteins. The antibodies targeting these proteins were used for their detection in human CCs by RPPA. The detection of protein VCL, SRC and ERK2 (by using an antibody already validated for RPPA) was then carried out on individual CCs and signals were detected for each individual sample. After normalisation by VCL, we showed that the level of expression of ERK2 was almost the same across the 13 individual CCs while the level of expression of SRC was different between the 13 individual CCs of the four patients and between the CCs from one individual patient. The exquisite sensitivity of RPPA allowed detection of specific proteins in individual CCs. Although the validation of antibodies for RPPA is labour intensive, RRPA is a sensitive and quantitative technique allowing the detection of specific proteins from very small quantities of biological samples. RPPA may be of great interest in clinical diagnostics to predict the oocyte competence prior to transfer of the embryo using robust protein biomarkers expressed by CCs

    Preferential beta-arrestin signalling at low receptor density revealed by functional characterization of the human FSH receptor A189 V mutation

    No full text
     The A189 V inactivating mutation of the human FSH receptor (FSHR) leads to subfertility in men and primary ovarian failure in women. This mutation has previously been associated with intracellular retention of the FSHR and impaired cAMP production. Here, we show that the A189 V FSHR stably expressed in HEK293N cells provoked ERK MAP kinases phosphorylation through β-arrestins, independently of the canonical cAMP/PKA pathway. Interesting, both the A189 V and wild-type (Wt) FSHRs selectively activated cAMP-independent ERK phosphorylation when expressed at low plasma membrane densities. These data indicate that the selective intracellular signalling triggered by the A189 V FSHR resulted from reduced membrane expression rather than by switching receptor coupling. Hence, receptor density at the plasma membrane might control the balance between distinct signal transduction mechanisms. Furthermore, our results help to clarify why mutations of FSHβ are more deleterious to human fertility than the FSHR A189 V mutation which preserves parts of receptor signalling repertoire
    corecore